secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001213900-25-053607
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma closes $6M registered direct offering with warrants for up to $9.8M additional proceeds
--------------------------------------------------------------------------------

- Gross proceeds of $6M from sale of 4.92M shares/pre-funded warrants at $1.22 per share.
- Short-term warrants to purchase up to 9.84M shares at $1.00; expire 24 months from issuance.
- Net proceeds ~$5.455M after fees; used for LYMPHIR commercial launch and corporate purposes.
- H.C. Wainwright placement agent; 7% cash fee plus placement agent warrants at $1.525 exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025053607/0001213900-25-053607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025053607/ea0245241-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-053607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer